Morbidity and Mortality after Induction Chemotherapy Followed by Surgery in IIIa-N2 non Small Cell Lung Cancer

被引:1
|
作者
Borreman, Ph. [1 ]
De Leyn, P. [1 ]
Decaluwe, H. [1 ]
Moons, J. [1 ]
Van Raemdonck, D. [1 ]
Nafteux, Ph. [1 ]
Coosemans, W. [1 ]
Lerut, T. [1 ]
机构
[1] Katholieke Univ Leuven Hosp, Dept Thorac Surg, Louvain, Belgium
关键词
Lung cancer; non-small-cell carcinoma; chemotherapy; adjuvant; pneumonectomy; PROLONGED AIR LEAK; PREOPERATIVE CHEMOTHERAPY; PULMONARY LOBECTOMY; COMORBIDITY SCORE; RESECTION; COMPLICATIONS; SYSTEM; PREDICTORS; THERAPY; POSSUM;
D O I
暂无
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective : To evaluate the frequency and risk of postoperative complications and mortality in patients with IIIa-N2 non small cell lung cancer after induction chemotherapy and surgery. Methods : In a surgical database records from ninety two patients, operated between January 1, 2000 and December 3 1, 2006 were reviewed. Univariate analysis was used to identify predictors of postoperative complications and in-hospital mortality. Results : All cases were histologically confirmed stage IIIa-N2. All patients received preoperative platinum based chemotherapy without radiotherapy. Pneumonectomy was performed in 20 cases (23.5%), from which 9 right sided. (Bi)lobectomy was performed in 53 cases (62.4%) and sleeve lobectomy in I I cases (17.2%). One wedge resection was performed (1.2%). In 7 cases (7.6%) only an exploration was done. Complications developed in 35 patients (38%). Major complications in 15 patients (16%). No bronchopleural fistulae were observed. Analysis identified increased age and high physiological and operative severity score for the enumeration of mortality and morbidity (POSSUM) as a risk factor to develop complications, and a high simplified comorbidity score as a risk factor to develop a major complication. Higher age, Charlson comorbidity index, simplified comorbidity score and POSSUM were a risk factor for developing pneumonia. Conclusion : Although surgery after induction therapy for IIIa-N2 NSCLC can be done with a morbidity and mortality comparable to surgery alone, it remains a high risk operation. It should therefore be performed in a center with experience. Bronchial stump protection should be used whenever there is an increased risk for developing a bronchopleural fistula. In deciding whether to do surgery or radiotherapy one should keep in mind the feasibility of performing a complete resection together with a preoperative assessment to predict complications and mortality. For the preoperative assessment several scoring systems can be used from which we find the simplified comorbidity score most useful.
引用
收藏
页码:333 / 339
页数:7
相关论文
共 50 条
  • [1] Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: Why pneumonectomy should be avoided
    Kappers, Ingrid
    van Sandicka, Johanna W.
    Burgers, Sjaak A.
    Belderbos, Jose S. A.
    van Zandwijk, Nico
    Klomp, Houke M.
    LUNG CANCER, 2010, 68 (02) : 222 - 227
  • [2] Mortality associated with pneumonectomy after induction chemoradiation versus chemotherapy alone in stage IIIA-N2 non-small cell lung cancer - Reply
    Darling, Gail
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2008, 135 (03): : 718 - 719
  • [3] Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer
    De Marinis, Filippo
    Gebbia, V.
    De Petris, L.
    ANNALS OF ONCOLOGY, 2005, 16 : 116 - 122
  • [4] Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer
    Tanaka, Fumihiro
    Yokomise, Hiroyasu
    Soejima, Toshinori
    Uramoto, Hidetaka
    Yamanaka, Takeharu
    Nakagawa, Kazuhiko
    Yamamoto, Nobuyuki
    Nishimura, Yasumasa
    Niwa, Hiroshi
    Okada, Morihito
    Nakagawa, Tatsuo
    Yamashita, Motohiro
    ANNALS OF THORACIC SURGERY, 2018, 106 (04): : 1018 - 1024
  • [5] Is surgery indicated for stage IIIA-N2 non-small-cell lung cancer?
    Gounant, V.
    Lavole, A.
    Epaud, C.
    Rosencher, L.
    Milleron, B.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2007, 63 (03) : 135 - 137
  • [6] Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery
    Shin, Sumin
    Kim, Hong Kwan
    Cho, Jong Ho
    Choi, Yong Soo
    Kim, Kwhanmien
    Kim, Jhingook
    Zo, Jae Ill
    Sun, Jong-Mu
    Ahn, Myung-Ju
    Park, Keunchil
    Pyo, Hongryull
    Ahn, Yong Chan
    Shim, Young Mog
    JOURNAL OF THORACIC DISEASE, 2020, 12 (05) : 2602 - 2613
  • [7] Role of surgery for stage IIIA-N2 non-small cell lung cancer
    Yang, Fan
    Wang, Jun
    THORACIC CANCER, 2011, 2 (03) : 90 - 94
  • [8] The prognostic significance of proliferative indices in surgically resected IIIA-N2 non-small cell lung cancer after induction chemotherapy
    Corzani, Roberto
    Luzzi, Luca
    Spina, Donatella
    Voltolini, Luca
    Paladini, Piero
    Ghiribelli, Claudia
    Ghisalberti, Marco
    Borrelli, Roberto
    Meniconi, Fabiola
    Monaci, Nicola
    Gotti, Giuseppe
    JOURNAL OF CARDIOVASCULAR SURGERY, 2017, 58 (05): : 763 - 769
  • [9] Resection of Persistent Stage IIIA-N2 Non-small Cell Lung Cancer After Induction Therapy
    Andrews, Weston G.
    Louie, Brian E.
    Bograd, Adam J.
    ANNALS OF THORACIC SURGERY, 2022, 114 (06): : 2392 - 2393
  • [10] Induction erlotinib therapy in stage IIIA-N2 non-small cell lung cancer
    Zhong Wen-Zhao
    Yang Xue-Ning
    Guo Ai-Lin
    Chen Hua-Jun
    Su Jian
    Liao Ri-Qiang
    Zhou Qing
    Nie Qiang
    Xu Chong-Rui
    Yang Jin-Ji
    Wu Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S590 - S591